Company intelligence / Profile preview

SolGent

Ownership: Private
Employees: ~80
Development stage: Commercial

Overview

SolGent has commercialized a range of molecular diagnostic products and research reagents. The company became the first in Korea to be designated by the U.S. FEMA as a stockpile procurement company for COVID‑19 test kits. It produces all core enzymes required for its test kits in-house—unique among Korean companies—and has achieved significant export success during the pandemic. Its products are noted for high sensitivity and accuracy[6]. The company also offers sequencing and genotyping services.

Therapeutic areas: Infectious Diseases
Modalities: PCR enzyme reagentsDiagnostic kits (including COVID-19 test kits)Sequencing services
Industry: Molecular Diagnostics

Drug pipeline

1 asset

DiaPlex Q

Commercial

Indications: COVID-19 diagnosis

Partnerships

Chinese partner company (for joint development of COVID–19 test kits)Noble Bio (for localization/optimization of tubes used in test kits)

Beyond the preview

Go deeper on SolGent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SolGent.

Explore the full profile